Listed

Celularity Inc

CELUNasdaqCIK 1752828HealthcareFiscal year ends Dec 31

Reports and events: 186 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Celularity Inc, Reports and events
FiledFormWhat it isAccession number
2023-06-2216:36 ETSC 13D/AOwnership report, active investor, amended0001140361-23-030962
2023-06-2116:17 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0000950170-23-029159
2023-06-1616:27 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000950170-23-028627
2023-05-3117:08 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-025401
2023-05-2216:29 ET10-QQuarterly reportPeriod 2023-03-310000950170-23-023462
2023-05-1916:26 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0000950170-23-023264
2023-05-1616:48 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0000950170-23-022503
2023-05-0109:00 ETDEF 14AProxy statementPeriod 2023-06-140001193125-23-128936
2023-04-2717:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-015374
2023-04-0720:58 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-094337
2023-03-3117:21 ET10-KAnnual reportPeriod 2022-12-310000950170-23-011440
2023-03-2309:06 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0000950170-23-009338
2023-03-1717:19 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-008663
2023-03-1717:17 ET8-K3.01 Delisting notice0000950170-23-008662
2023-03-1308:56 ET8-K7.01 Regulation FD disclosure0000950170-23-007462
2023-01-3016:30 ET8-K5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-001378
2022-12-1608:38 ET8-K8.01 Other events0000950170-22-026638
2022-11-1016:29 ET10-QQuarterly reportPeriod 2022-09-300000950170-22-024523
2022-11-1016:19 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-22-024493
2022-10-0616:08 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-258852
2022-09-2316:05 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-250130
2022-09-1516:11 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001193125-22-245623
2022-09-0808:48 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-22-240629
2022-08-1019:22 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-22-216404
2022-08-0916:31 ET10-QQuarterly reportPeriod 2022-06-300001564590-22-028775
2022-07-2016:07 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-198101
2022-07-1517:17 ET10-K/AAnnual report, amendedPeriod 2021-12-310001193125-22-195133
2022-07-1416:06 ET8-K5.07 Shareholder vote results0001193125-22-193761
2022-06-1716:57 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-176615
2022-06-0316:46 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-167406
2022-06-0316:40 ETDEF 14AProxy statementPeriod 2022-07-130001193125-22-167393
2022-05-2521:01 ETS-1Registration statement0001193125-22-158801
2022-05-2016:06 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-156126
2022-05-1616:47 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-22-151903
2022-05-1616:39 ET10-QQuarterly reportPeriod 2022-03-310001564590-22-020422
2022-05-1106:09 ETS-1/ARegistration statement, amended0001193125-22-146808
2022-05-0316:11 ET8-K8.01 Other events0001193125-22-138682
2022-04-2907:31 ETS-1Registration statement0001193125-22-130204
2022-03-3116:17 ET10-KAnnual reportPeriod 2021-12-310001564590-22-013004
2022-03-3116:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-22-012992
2022-03-1616:06 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-077225
2022-03-0116:47 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001193125-22-061431
2022-02-1608:31 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-044020
2022-01-1816:06 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-011229
2021-12-2816:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-21-367920
2021-12-1708:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-21-360062
2021-11-1216:38 ET10-QQuarterly reportPeriod 2021-09-300001564590-21-056724
2021-11-1216:19 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-056712
2021-09-1516:49 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001213900-21-048256
2021-08-2019:35 ET8-K/A9.01 Financial statements and exhibits0001213900-21-043933

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 11, 2026, 02:51 ET. Listed shows no prices and gives no investment advice.